Alopecia Areata has no cure, treatments are limited, and the condition often recurs, but new therapies like JAK inhibitors show promise.
January 2016 in “Springer eBooks” Alopecia Areata is an unpredictable autoimmune hair loss condition with limited and variable treatment effectiveness.
12 citations
,
June 2023 in “JAMA network open” JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” JAK inhibitors can help regrow hair in alopecia areata but have potential long-term risks and require careful monitoring.
138 citations
,
March 2021 in “Journal of the American Academy of Dermatology” Ritlecitinib and brepocitinib effectively regrow hair in alopecia areata patients.
49 citations
,
August 2018 in “International Journal of Dermatology” Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.
January 2025 in “FASKES Jurnal Farmasi Kesehatan dan Sains” Erythrina subumbrans leaves may help treat hair loss.
290 citations
,
December 2017 in “Journal of The American Academy of Dermatology” Alopecia areata is an autoimmune condition causing hair loss, influenced by genetics, stress, and diet, and may be prevented by a high soy oil diet.
182 citations
,
December 2017 in “Journal of the American Academy of Dermatology” Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.
159 citations
,
October 2015 in “Science Advances” Blocking JAK-STAT signaling can lead to hair growth.
130 citations
,
February 2019 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” JAK inhibitors are effective for treating alopecia areata, with most patients seeing hair growth after treatment.
55 citations
,
October 2015 in “Journal of Investigative Dermatology” Alopecia areata is linked to immune-related genes, suggesting JAK inhibitors as a potential treatment.
51 citations
,
October 2019 in “Cells” Baricitinib reduces inflammation and improves cell health in premature aging cells.
49 citations
,
March 2017 in “Journal of the American Academy of Dermatology” Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
40 citations
,
September 2018 in “Journal of the American Academy of Dermatology” Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.
40 citations
,
April 2014 in “Genes & Development” Hormones during pregnancy and lactation keep skin stem cells inactive, preventing hair growth.
37 citations
,
January 2016 in “Drug design, development and therapy” Tofacitinib citrate is effective for moderate-to-severe chronic plaque psoriasis but has safety concerns at higher doses.
36 citations
,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
36 citations
,
January 2021 in “Scientific Reports” Key genes and pathways, including Wnt, NF-Kappa, and JAK-STAT, are crucial for starting Pashmina fiber growth in goats.
29 citations
,
December 2019 in “Expert review of clinical pharmacology” JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.
28 citations
,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
24 citations
,
October 2018 in “JAAD Case Reports” A woman's eyelash regrowth was successful using tofacitinib solution for alopecia areata.
23 citations
,
August 2022 in “JAMA Dermatology” Patients with alopecia areata feel less regret about treatment decisions when they are involved in the decision-making process.
20 citations
,
March 2023 in “American Journal of Clinical Dermatology” Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
20 citations
,
June 2019 in “JAAD Case Reports” Tofacitinib can cause skin eruptions similar to palmoplantar pustulosis.
14 citations
,
April 2021 in “International journal of molecular sciences” Mesenchymal stem cells may help treat hair loss by improving hair cell growth and reducing inflammation.
13 citations
,
September 2018 in “Journal of the American Academy of Dermatology” The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.
12 citations
,
December 2022 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.
11 citations
,
September 2024 in “American Journal of Clinical Dermatology” Switching JAK inhibitors or using dupilumab may help some alopecia areata patients who don't respond well to initial treatments.
11 citations
,
December 2018 in “Journal of the European Academy of Dermatology and Venereology” Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.